Invivyd, a developer of antibody‑based therapeutics, announced the nomination of VBY329 for preclinical development as a next‑generation monoclonal antibody to prevent respiratory syncytial virus (RSV) in neonates, infants and children. The candidate was identified through Invivyd’s proprietary INVYMAB platform, which screens for antibodies that bind conserved viral epitopes, enabling broad variant coverage and high potency.
VBY329 demonstrates a 1.5‑fold increase in in‑vitro neutralization potency over the market leader nirsevimab and a 1.2‑fold increase over clesrovimab. In pseudovirus assays, the antibody achieved up to 500‑fold enhanced neutralization against nirsevimab‑resistant RSV F protein variants, while binding both RSV‑A2 and RSV‑B subtypes. These data suggest that VBY329 could offer superior protection and address strains that evade current therapies.
The company plans to advance VBY329 to IND‑enabling studies with a target readiness in the second half of 2026, positioning the candidate for a potential launch in the rapidly expanding pediatric RSV prophylaxis market, projected to reach $3‑$4 billion in annual revenues globally by 2030. RSV remains the leading cause of hospitalization for infants in the United States, underscoring the unmet need for improved prevention options.
Invivyd’s CEO, Robert Allen, said, “Our INVYMAB platform has enabled us to identify a candidate with markedly superior potency and broader variant coverage. VBY329 represents a significant step forward in our effort to deliver next‑generation RSV prophylaxis.” The announcement signals a strategic shift beyond the company’s COVID‑19 portfolio, diversifying its pipeline and reducing reliance on a single therapeutic area.
Investors welcomed the news, citing the candidate’s superior potency, broader coverage and the company’s strong platform technology as key differentiators. The announcement follows a $125 million public offering completed on November 17, 2025, which provides additional capital to support the accelerated development of VBY329 and other pipeline candidates.
Invivyd’s pipeline also includes next‑generation COVID‑19 antibodies such as VYD2311, which has received IND clearance and is advancing into Phase 3 trials, as well as early‑stage programs for measles and influenza. The company’s gross profit margin of 93.3% and $50 million in revenue over the past twelve months demonstrate robust financial health, supporting continued investment in high‑potential antibody candidates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.